Drug intelligence / Profile preview

LY3079514

Development stage: Phase 1
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Intravenous, Subcutaneous

Overview

LY3079514 is a small molecule drug developed by Eli Lilly. It has been evaluated in phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers. The mechanism of action for LY3079514 is currently unknown. There are no approved indications or known adverse events reported for this compound. The drug has been administered via intravenous and subcutaneous routes in studies[1][2][3].

Targets

PORCN (Porcupine protein)

Beyond the preview

Go deeper on LY3079514.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY3079514.

Explore the full profile